Novartis Oncology delivers a broad range of innovative therapies to potentially improve and extend the lives of patients.  These include Gleevec® (imatinib mesylate), Exjade® (deferasirox), Zometa® (zoledronic acid), Sandostatin LAR® Depot (octreotide acetate for injectable suspension) and Femara® (letrozole tablets).  Novartis Oncology has a robust pipeline capitalizing on recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.